Posts Tagged ‘ Alex Gorsky ’

Ethicon Trial Opening Statements Thursday

Jan 8th, 2013 | By
Ethicon Trial Opening Statements Thursday

January 8, 2013 ~ Jurors are being selected today for the first of 1,974 lawsuits to be heard in a New Jersey state court against Johnson & Johnson, maker of the Gynecare Prolift Pelvic Floor Repair System (here) transvaginal mesh. Plaintiff Linda Gross from Watertown, South Dakota and her lawyers argue that Ethicon, a division
[continue reading...]



J & J Execs to be Deposed About Vaginal Mesh – What Did They Know – When Did They Know It

Jul 29th, 2012 | By
J & J Execs to be Deposed About Vaginal Mesh – What Did They Know – When Did They Know It

July 29, 2012 ~ Johnson & Johnson’s new CEO is on the hot seat. Alex Gorsky must show up to provide a videotaped deposition concerning the upcoming Ethicon transvaginal mesh lawsuits pending before a New Jersey Superior Court. Ethicon is a wholly owned subsidiary of Johnson & Johnson. The decision to require Gorsky and two
[continue reading...]



Could J & J Implosion Lead to Better Oversight?

Jul 20th, 2012 | By
Could J & J Implosion Lead to Better Oversight?

July 19, 2012 ~ Is more corporate oversight needed by Johnson & Johnson? After years of defective medications, contaminated children’s cold products, three closed manufacturing plants still in FDA hands , defective recalled metal hips, dangerous synthetic vaginal mesh the focus of thousands of lawsuits, kickbacks to docs to speed up sales, and illegally promoting
[continue reading...]



New J & J CEO Plans to Expand Medical Device Industry

Apr 30th, 2012 | By
New J & J CEO Plans to Expand Medical Device Industry

  It will be interesting to watch how Alex Gorsky, 51, handles his new job and all that comes with it. As of April 26, he is in charge of Johnson & Johnson (J&J) as its Chief Executive Officer. He also inherited a massive number of lawsuits from surgical mesh and defective metal hip devices.
[continue reading...]



We hope you find this a helpful resource. National News Editor, Jane Akre, began MDND with the hope of providing the latest news, information and perspective from the regulatory, industry and patient point of view, something that goes under-reported in much of the coverage of medical devices. The public is just now becoming aware that many devices do not undergo the same scrutiny as prescription drugs and are instead grandfathered in under an FDA loophole that has gone largely unchanged since the 1970s. As a result, patients become the post-market clinical trial subjects, and many suffer devastating and permanent injuries.